series-c-plus
Stage
1
Investors
About
NewLimit is inventing medicines to radically extend healthy human lifespan by reversing cellular aging through epigenetic reprogramming. They use an AI-driven discovery engine to design and test transcription-factor payloads that restore youthful function in old cells, with initial programs targeting the liver, immune system, and vasculature.
Explore NewLimit's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.